Pharmacological inhibition of MET impairs hepatic regeneration and recovery in a murine model of acetaminophen-induced liver injury
- 1Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- 2Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
BACKGROUND AND OBJECTIVE: Hepatocyte growth factor receptor (MET) is the key driver of liver regeneration following partial hepatectomy (PHx) but remains poorly understood in the context of acetaminophen-induced liver injury (AILI). In our prior work, hepatocyte-specific MET-knockout mice exhibited severe early injury and high mortality following APAP overdose, limiting the evaluation of MET's direct role in liver regeneration. Given the critical need to identify therapeutic targets that promote recovery during the late stages of AILI, the present study investigates the reparative role of MET using a pharmacological MET inhibitor, capmatinib. METHODS: C57BL/6 J mice (n = 5) received moderate (300 mg/kg) or severe (500 mg/kg) overdose of APAP, followed by capmatinib (15 mg/kg) or vehicle. Liver injury and regeneration parameters were assessed using histology, immunoblotting, and immunohistochemistry. RESULTS: Vehicle and capmatinib-treated mice showed comparable peak injury under both moderate and severe APAP overdose settings, enabling a direct assessment of regeneration independent of initial injury severity. During the recovery phase, capmatinib-treated mice displayed significant impairment in resolution of injury (p < 0.05), indicated by sustained centrilobular necrosis, especially after severe APAP overdose. While MET inhibition delayed and dampened hepatocyte proliferation response following moderate APAP overdose, it severely impaired hepatocyte proliferation following the higher APAP overdose. Impaired liver regeneration upon MET inhibition was associated with marked reduction in ERK signaling and downstream expression of core cell cycle protein, cyclin-D1. CONCLUSIONS: Overall, MET inhibition using capmatinib notably impaired regeneration and resolution of AILI, without altering peak injury, emphasizing MET's direct role in reparative response.
Related
- New insights on iron overload-mediated lysosomal membrane rupture in liver regeneration following acetaminophen-induced liver injury.
- Immune-stimulatory cytokine IL-18 induces inflammatory senescence and impairs stem cell-mediated experimental skeletal regeneration
- Loss of LanC-like proteins impairs post-injury regeneration of aging muscles
- Menin inhibition impairs metastatic colonization of Ewing sarcoma
- Group IVA Cytosolic Phospholipase A2 (cPLA2α): Pharmacological Inhibition Attenuates Kidney Inflammation and Fibrosis
BibTeX
@article{jain2026pharmacological,
title = {{Pharmacological inhibition of MET impairs hepatic regeneration and recovery in a murine model of acetaminophen-induced liver injury}},
author = {Siddhi Jain and Ranjan Mukherjee and Gillian Williams and Anne Orr and Saidikrom Mardiev and George K Michalopoulos and Bharat Bhushan},
journal = {Toxicology and applied pharmacology},
year = {2026},
month = oct,
doi = {10.1016/j.taap.2026.118079},
url = {https://doi.org/10.1016/j.taap.2026.118079},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pharmacological inhibition of MET impairs hepatic regeneration and recovery in a murine model of acetaminophen-induced liver injury
AU - Siddhi Jain
AU - Ranjan Mukherjee
AU - Gillian Williams
AU - Anne Orr
AU - Saidikrom Mardiev
AU - George K Michalopoulos
AU - Bharat Bhushan
PY - 2026
DA - 2026/10/09
JO - Toxicology and applied pharmacology
DO - 10.1016/j.taap.2026.118079
UR - https://doi.org/10.1016/j.taap.2026.118079
AB - BACKGROUND AND OBJECTIVE: Hepatocyte growth factor receptor (MET) is the key driver of liver regeneration following partial hepatectomy (PHx) but remains poorly understood in the context of acetaminophen-induced liver injury (AILI). In our prior work, hepatocyte-specific MET-knockout mice exhibited severe early injury and high mortality following APAP overdose, limiting the evaluation of MET's direct role in liver regeneration. Given the critical need to identify therapeutic targets that promote recovery during the late stages of AILI, the present study investigates the reparative role of MET using a pharmacological MET inhibitor, capmatinib. METHODS: C57BL/6 J mice (n = 5) received moderate (300 mg/kg) or severe (500 mg/kg) overdose of APAP, followed by capmatinib (15 mg/kg) or vehicle. Liver injury and regeneration parameters were assessed using histology, immunoblotting, and immunohistochemistry. RESULTS: Vehicle and capmatinib-treated mice showed comparable peak injury under both moderate and severe APAP overdose settings, enabling a direct assessment of regeneration independent of initial injury severity. During the recovery phase, capmatinib-treated mice displayed significant impairment in resolution of injury (p < 0.05), indicated by sustained centrilobular necrosis, especially after severe APAP overdose. While MET inhibition delayed and dampened hepatocyte proliferation response following moderate APAP overdose, it severely impaired hepatocyte proliferation following the higher APAP overdose. Impaired liver regeneration upon MET inhibition was associated with marked reduction in ERK signaling and downstream expression of core cell cycle protein, cyclin-D1. CONCLUSIONS: Overall, MET inhibition using capmatinib notably impaired regeneration and resolution of AILI, without altering peak injury, emphasizing MET's direct role in reparative response.
SN - 0041-008X
SN - 1096-0333
ER -